
    
      A Phase 1b/2 open-label, intrapatient dose escalation study aiming to evaluate the safety,
      tolerability, immunogenicity, biological and pharmacodynamic activity of intravenous
      ATYR1940, administered once weekly for 12 weeks, in early onset FSHD patients with signs or
      symptoms prior to 10 years of age. In Stage 1, up to 8 patients between the ages of 16 and 25
      years will be enrolled. Stage 2 of enrollment will include patients with early onset FSHD
      between the ages of 12 and 15 years.
    
  